CD44 and glioblastoma: In line with the vast body of evidence implicating CD44 in glioma progression [16], we observed a significant reduction in the proliferative capacity of the well-established GBM in vitro model U251MG, upon depletion of CD44 by CRISPR/Cas9 gene editing.